ELECSYS ANTI-HCV IMMUNOASSAY

Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus

FDA Premarket Approval P090008 S006

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

Approval for the extension of the elecsys anti-hcv immunoassay andprecicontrol anti-hcv immunoassay onto the cobas e 602 immunoassay analyzer. The device, as modified, will be marketed under the trade name elecsys anti-hcv immunoassay and is indicated for: elecsys anti-hcv immunoassay - the elecsys anti-hcv immunoassay is an in vitro diagnostic test for the qualitativedetection of total antibodies to hepatitis c virus (anti-hcv) in human serum or plasma (potassium edta, lithium heparin and sodium heparin). Assay results, in conjunction with other laboratory results and clinical information, may be used to aid in the presumptive diagnosis of hcv infection in persons with signs and symptoms of hepatitis and in persons at risk for hepatitis c infection. This test does not determine the state of infection or associated disease. The electrochemiluminescence immunoassay "eclia" is intended for use on cobas e 601 and cobas e 602 immunoassay analyzers.

DeviceELECSYS ANTI-HCV IMMUNOASSAY
Classification NameAssay, Enzyme Linked Immunosorbent, Hepatitis C Virus
Generic NameAssay, Enzyme Linked Immunosorbent, Hepatitis C Virus
ApplicantROCHE DIAGNOSTICS CORP.
Date Received2011-11-01
Decision Date2012-04-25
PMAP090008
SupplementS006
Product CodeMZO
Advisory CommitteeMicrobiology
Supplement TypeNormal 180 Day Track
Supplement ReasonChange Design/components/specifications/material
Expedited ReviewNo
Combination Product No
Applicant Address ROCHE DIAGNOSTICS CORP. 9115 Hague Rd. indianapolis, IN 46250

Supplemental Filings

Supplement NumberDateSupplement Type
P090008Original Filing
S023 2022-09-30 Real-time Process
S022
S021 2018-10-26 Normal 180 Day Track No User Fee
S020 2018-04-17 Real-time Process
S019 2017-10-11 Real-time Process
S018 2017-08-03 30-day Notice
S017 2016-02-16 30-day Notice
S016 2016-01-27 30-day Notice
S015 2015-10-07 30-day Notice
S014 2014-08-22 30-day Notice
S013 2014-04-04 Real-time Process
S012 2012-11-30 30-day Notice
S011 2012-09-05 30-day Notice
S010
S009 2012-02-29 30-day Notice
S008 2012-01-31 135 Review Track For 30-day Notice
S007 2011-11-21 30-day Notice
S006 2011-11-01 Normal 180 Day Track
S005 2011-08-29 135 Review Track For 30-day Notice
S004 2011-08-17 135 Review Track For 30-day Notice
S003 2011-05-17 Normal 180 Day Track No User Fee
S002 2011-04-11 30-day Notice
S001 2010-07-28 Normal 180 Day Track

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.